SSGJ-707

Phase 3Small molecule

SSunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.

SSGJ-707 is one of 54 small molecule programs targeting Metastatic Colorectal Cancer. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Metastatic Colorectal CancerActive, not recruiting

Non-Small Cell Lung CancerActive, not recruiting

Metastatic Colorectal CancerPhase 2

Active, not recruiting

Non-Small Cell Lung CancerPhase 3

Active, not recruiting

Competition

Competitive Landscape

1639 competitors in Non-Small Cell Lung Cancer

#DrugCompanyPhaseTrials

Gemzar

GGynecologic Oncology Group

Preclinical

72 2

SSGJ-707

SSunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.

Phase 3

1 3

PORTRAZZA

Eli Lilly

Preclinical

8 4

Lenvima

Eisai

Preclinical

6 5

Ofev

Boehringer Ingelheim

Preclinical

7 6

Remeron

OOrganon and Co

Preclinical

1 7

PD-1 Inhibitor

Johnson & Johnson

Preclinical

2 8

Aqupla

Jiangsu Simcere Pharmaceutical Co., Ltd.

Preclinical

—9

Ftorafur

TThe First Affiliated Hospital with Nanjing Medical University

Vidaza

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

Phase 2Recruiting

Gynecologic Cancer

NCT06522828

Q2 2027

Phase 2Recruiting

Metastatic Colorectal Cancer

NCT06493760

Q4 2028

Phase 3Recruiting

Non-Small Cell Lung Cancer

NCT06980272

Clinical

Trials by Indication[1]

Non-Small Cell Lung Cancer1 trial

SSGJ-707 in Advanced Non-Small Cell Lung Cancer

Recruiting·SShenyang Sunshine Pharmaceutical Co., LTD.·Phase 3·NCT06980272·420 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for SSGJ-707. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — SSGJ-707 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for SSGJ-707. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: SSunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.

SSGJ-707

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2026

Q2 2027

Q4 2028

Trials by Indication[1]

Non-Small Cell Lung Cancer1 trial

Metastatic Colorectal Cancer1 trial

Combination Therapy1 trial

Advanced NSCLC1 trial

Gynecologic Cancer1 trial

References

Drug Info

Quick Facts

Related News